# Human Intelligence Enhanced by Artificial Intelligence

A REVOLUTION IN CARDIOVASCULAR IDENTIFICATION AND MANAGEMENT

### CardioCare

Digital Health Platform

The CardioCare platform helps physicians identify and manage at-risk valvular heart disease (VHD) patients to improve outcomes.

THE PREVALENCE OF VALVULAR HEART DISEASE CONTINUES TO BE SUBSTANTIAL AND MORE COMMON AS PATIENTS AGE<sup>1</sup>

**7.1%** TR

MR **6.5**%

4.1% AS

AR 2.3%

**0.5%** MS

<sup>1</sup>Brennan JM, et al. Poster presented at: American College of Cardiology 71st Annual Scientific Session & Expo; April 2-4, 2022; Washington, DC.; Brennan JM, et al. JACC 2022

aortic regurgitation (AR), aortic stenosis (AS), mitral regurgitation (MR), mitral stenosis (MS), tricuspid regurgitation (TR)






Hospital systems face significant challenges that may unintentionally delay patient care. Poor outcomes and high mortality are possible consequences of delayed therapy for patients with severe VHD.

Artificial intelligence solutions, like the CardioCare platform, are a better way to improve efficiencies and help hospital systems identify at-risk patients.

#### HELPING PHYSICIANS PREDICT THE PROGRESSION OF MODERATE AS



The CardioCare platform applies Artificial Intelligence (AI) to your hospital's echos and uses proprietary predictive algorithms to help physicians identify patients who may have progressed from moderate to severe disease.<sup>2</sup>

## The CardioCare platform helps physicians improve the quality of care for VHD patients<sup>3</sup>







<sup>2</sup>Moualla SK, et al. J Am Coll Cardiol. 2021;78(19\_Suppl\_S):B24. Moualla SK, et al. Intelligence-Based Medicine. In Press. doi: 10.1016/j.ibmed.2022.100062

<sup>3</sup>Analysis represents median growth from 8 CardioCare sites with baseline data one year after implementing the CardioCare platform.

#### For more information, please visit egnitehealth.com/solutions

The CardioCare platform is not intended for use in the diagnosis, cure, mitigation, or prevention of cardiovascular diseases.

©2022 egnite, Inc. All Rights Reserved. egnite, egnite Inc., the spark logo, CardioCare, and the heart logo are trademarks of egnite, Inc or its affiliates. All other trademarks are property of their respective owners.

